Background and Aims: A biosimilar version of infliximab [CT-P13/Remsima®] recently entered the European market. The clinical data on its use in inflammatory bowel disease [IBD] are sparse, especially on switching from the originator Remicade®. In this study, we aimed to prospectively investigate the feasibility, safety and immunogenicity of switching from Remicade to Remsima in a real-life IBD population. Methods: All adult patients who were treated with Remicade in the Department of Gastroenterology at Oslo University Hospital were switched to Remsima. The follow-up lasted for 6 months. In addition, a retrospective registration was performed with a start time of 6 months before switching drugs. The primary endpoints were [i] the proportion of patients remaining on medication 6 months after switching and [ii] adverse events during the 6 months after switching. The secondary endpoints included [i] disease activity scores [Harvey-Bradshaw Index and Partial Mayo Score], C-reactive protein, haemoglobin, faecal calprotectin, infliximab dose and interval, and p-infliximab and [ii] the development of antidrug antibodies. Results: In total, 143 IBD patients were switched, 99 with Crohn's disease and 44 with ulcerative colitis. The large majority [97%] remained on the medication throughout follow-up. A low number of adverse events were observed. No change in disease activity, C-reactive protein, haemoglobin, faecal calprotectin, infliximab dose and interval or p-infliximab was detected. Three patients developed new detectable antidrug antibodies. Conclusions: Switching from Remicade to Remsima was feasible and with few adverse events, including very limited antidrug antibody formation and loss of response.
Introduction
Biological agents such as anti-tumour necrosis factor alpha [anti-TNF-α] are effective in inducing and maintaining remission in patients with moderate to severe inflammatory bowel disease [IBD] . [1] [2] [3] Infliximab [IFX] was the first anti-TNF-α drug approved to treat IBD in 1998, and it has improved the clinical outcome for this group of patients. When the patent protection of this agent expired, lower-priced biosimilars entered the market. In 2013, the biosimilar of Remicade® [infliximab; Janssen Biologics, Leiden 4 Concerns have been raised, especially about the validity of the extrapolation, and whether AS and RA were actually the most appropriate patient groups to be investigated. 5 Clinical, real-life data about CT-P13 in IBD patients are currently sparse. Smaller clinical studies have shown that CT-P13 is well tolerated and efficient in IFX-naïve patients; [6] [7] [8] [9] however, switching between the IFX originator and its biosimilar has only been reported in a few studies including a limited number of patients. [10] [11] [12] [13] Concurrently, the rising incidence of IBD combined with an increasing use of biological agents has resulted in a growing economic burden on public health care. Consequently, there has been an expressed objective from the health care administration in many countries to introduce biosimilars to reduce costs. As an example, biosimilars were included in the national tender system [LIS] in Norway, and following the LIS negotiations in 2014, Remsima was priced 39% lower than the originator, Remicade. In 2015, the price difference between Remicade and Remsima was 72%, and switching was strongly recommended by the Regional Health Authority.
The aims of the present study were to assess the feasibility, safety and immunogenicity of switching from Remicade to Remsima in a real-life IBD population.
Materials and methods
This is a prospective, open-label study from a single centre in Norway. All adult [≥18 years] IBD patients in the IBD unit at Oslo University Hospital who were treated with Remicade were switched to the biosimilar, Remsima, between September 9, 2015 and November 25, 2015 regardless of disease activity and concomitant treatments. The reason for switching to the biosimilar drug was cost reduction. The patients were followed prospectively for 6 months after switching. Additionally, a retrospective registration of data with a start time of 6 months before switching was performed in the same patients.
At 16 for UC). All adverse events and changes in medication were recorded.
The data collected from the 6 months prior to switching included the IFX dose and treatment interval, Hgb, CRP, FC and p-IFX.
Individual dose optimization, based on p-IFX and clinical assessment, was performed consecutively. Because of differences in the length of treatment intervals, the results from 3 and 6 months before as well as 3 and 6 months after switching are presented as pooled data. To obtain a standardized measure to report changes in the dose and length of intervals, a combined ratio of mg Remsima per kg body weight per week [mg/kg/week] was calculated. Drug levels were measured using a target-based assay, with TNF on the solid phase, the active drug in the patient sample binding TNF on the solid phase and a europium-labelled tracer that binds the Fc-domain on the drug. The lowest reported concentration for IFX was 1 mg/l, and levels below this concentration were considered negative.
Disease activity
ADAs were measured using an assay measuring only antibodies binding the TNF-binding site of the drug. As a rule, the assay is drug-sensitive; it primarily detects ADAs not bound to IFX. Rarely, the assay detects ADAs when the concentration of free drug exceeds 1 mg/l. For this study, only samples with drug levels <1 mg/l were analysed further for ADAs. Samples with ADA concentrations <10 AU/l were considered negative, >10 AU/l low levels, >30 AU/l moderate levels and >80 AU/l high positive.
Statistical analysis
All continuous data are expressed as the median (range or interquartile range [IQR]) or mean (standard deviation [SD]) when appropriate. Categorical data are presented as counts and percentages. For the continuous variables CRP, Hgb, FC, p-IFX and mg/kg/week, the change over time before and after switch was analysed using linear mixed models for repeated measures. Fixed effects of time were estimated, and diagnosis, gender and age were included in the analysis as possible confounders. As all measurements were made at equally distributed time points, a diagonal covariate matrix was used to estimate dependencies between measurements. All overall effects were analysed using the F-test. The results are presented as estimated marginal means with 95% confidence intervals [CI] . Values of p<0.05 were considered statistically significant. The software program IBM SPSS Statistics, version 22 [SPSS Inc., Chicago, IL, USA] was used for statistical analyses.
Ethics
The study was approved as a quality assurance study by the local data protection officer. Only data from standard clinical follow-up were included in the study database, and all patients signed informed consent regarding their willingness to include their data in the study database.
Results
In total, 143 IBD patients were switched from Remicade to Remsima and included in the study. The patient disposition is depicted in a Consolidated Standards of Reporting Trials [CONSORT]-style diagram [ Figure 1 ].
The cohort included 99 CD patients and 44 UC patients, with 36% females. The patient characteristics are summarized in Table 1 
Adverse events
Adverse events were observed in three patients with UC and in 14 patients with CD [ 
Disease activity

Change in activity scores
No significant changes in disease activity defined by HGBI for CD and PMS for UC were observed after the switch from Remicade to Remsima [ Figure 2 ]. The proportion of patients in clinical remission defined by activity scores was 87% for CD and 88% for UC at week zero versus 81% for CD and 95% for UC at the 6-months follow-up. 
Impact on biochemical surrogates of inflammation
No statistically significant changes in biochemical markers of inflammation [CRP, Hgb and FC] were detected. The proportion of patients with biochemical signs of disease activity [i.e. CRP >4 mg/l, FC >250 mg/kg and anaemia] before and after switch is shown in Figure 3 . In the linear mixed model regression analysis, no statistically significant change in CRP, Hgb or FC was observed over time or at any selected time point, either before or after switch [ Table 3 ].
Change in IFX dosage
In 33 patients [23%], IFX treatment was intensified in terms of an increased dose [n=25] or a shortening of the dose interval [n=8] during the follow-up. Eleven of these changes were already implemented at inclusion. Nineteen of the changes were based on low or decreasing p-IFX levels. The remaining changes were due to increasing activity index scores or a major increase in FC. In five of these cases, the treatment intensification was transient. Ten patients had their dose reduced or interval increased. In addition, four patients received a course of systemic prednisolone or started azathioprin [AZA] . In one patient with severe CD, vedolizumab was added to the present treatment with Remsima during follow-up because of longlasting high activity despite the high dosage of IFX treatment. After this, CRP slowly normalized. The treatment with simultaneous IFX and vedolizumab was planned as a transitional phase until response and eventually remission was achieved.
IFX dosage [mg/kg/week] and p-IFX
The doses and treatment intervals varied considerably between patients. However, no change in the combined measure of mg/kg/ week was observed either during the 6 months previous to switching or during the 6-month observation period [p=0.62 before and 0.95 after switch] [ Figure 4 and Table 3 ]. There was no significant change in p-IFX over time [p=0.07 before and 0.54 after switch] [ Figure 4 and to increase her dose of IFX despite low p-IFX, and one patient stopped methotrexate treatment [because of nausea] prior to ADA detection. In all these patients, the ADAs were transient [i.e. fewer than two consecutive measures of detectable ADAs 20, 21 ], and they continued medical treatment with Remsima during the 6-month observation period.
Discussion
In this prospective, open-label study including 143 IBD patients switching from the originator Remicade to the biosimilar Remsima, 97% of the patients continued on the IFX biosimilar medication during the 6-month follow-up. Few adverse events and infusion reactions were observed. Switching did not result in a significant change in disease activity scores. The inflammatory biomarkers CRP, Hgb and FC, as well as the pharmacokinetic parameters p-IFX and IFX mg/kg/week, were similar during the 12-month observation period [6 months prior to switch to 6 months after switch]. In 23% of the patients, IFX treatment was escalated in terms of an increased dose or a shortening of the interval.
The literature suggests that a loss of response is observed in approximately 13% of patients on anti-TNF-α therapy every year 22, 23 and that most of these patients can be handled with increased doses No patients reported more than one adverse event *Stopped treatment due to the adverse event UC: ulcerative colitis, CD: Crohn's disease or switching to another anti-TNF-α medication. In the present study, no patients had to discontinue IFX treatment due to a loss of response, which could be explained by the high number of escalations. Most escalations were based on p-IFX alone and not because of a change in clinical or biochemical measures. Infliximab is a chimeric monoclonal antibody containing a variable region with immunogenic murine sequences. The appearance of ADAs reactive to these sequences is often associated with loss of therapeutic efficacy. These ADAs are commonly measured using double antigen 'bridging' assays in which infliximab is used as both solid-phase and tracer. When comparing ADA responses in patients receiving originator or biosimilar drugs, choice of an appropriate calibration strategy is critical. 24 In the present study ADAs were measured using an inhibition assay with anti-TNF-α solid phase and a lanthanide-labelled infliximab tracer. This approach allows the preferential detection of moderate-to high-affinity neutralizing antibodies.
Originator and biosimilars are manufactured using complex production processes which could potentially result in variations in immunogenicity. 25 However, results from a number of clinical trials including the PLANETRA study have failed to detect significant differences in immunogenicity between Remicade and Remsima. 26 Three patients developed new detectable ADAs, while two patients had detectable ADAs at inclusion [5/143, 3 .5%]. Patients with low or intermediate levels of ADAs normally receive increased doses of infliximab and/or complementary treatment with methotrexate [MTX] or AZA. In the five patients who had measurable ADAs in this study, the ADAs were transient, and all patients continued on treatment until the end of observation.
The reported frequencies of ADAs range between 6 and 46% in patients treated with scheduled infliximab. [27] [28] [29] Ungar et al. found that 90% of patients who developed sustained ADAs did so within the first 12 months of therapy [4-year follow-up]. They also found transient ADAs in 26% of patients, not preferentially during the first year of medication. 27 Smits et al. found detectable ADAs to infliximab in 7/83 patients [8%] in their switch cohort during 16 weeks of follow-up, including five patients who had detectable ADA levels at baseline. 12 The high drug survival and low ADA formation observed in the present study might reflect a close follow-up, including drug monitoring [p-IFX, ADAs], regular clinical assessment and measurement of inflammatory markers. Moreover, the patients had a minimum of 10 months of continuous treatment with Remicade at inclusion and stable inflammatory markers during the 6 months before switch. Thus, they probably represent a group of patients with sufficient treatment response.
A low number of adverse events was registered during follow-up. This is consistent with available data that suggest that long term anti-TNF-α therapy is well tolerated, although an elevated risk of serious infections and skin cancer have been reported. 30 One male CD patient aged 30 years was diagnosed with lymphoma. He had a short history with AZA, but this medication was discontinued before he started treatment with Remicade more than 5 years before switching. He developed symptoms of chest pain and dyspnoea 1 month after switching and was diagnosed with B-cell lymphoma 3 months after switching. The available data do not suggest an increased incidence of lymphoma in CD patients treated with IFX compared to those without IFX. 30 We consider it clinically unlikely that switching from Remicade to Remsima had any aetiological association with the development of lymphoma.
The reported prevalence of acute infusion reactions to infliximab range from 3 to 20%, and thus our finding of 0.7% is low. 31 This could be explained by the long duration of infliximab use [at least 10 months prior to switch] in the study population and the fact that most adverse reactions are observed during induction or the first year of treatment. The presence of antibodies to IFX has been associated with an increased risk of infusion reactions, 32 but ADAs were not observed in the two patients with infusion reactions in the present study.
Switching from Remicade to a biosimilar IFX has been reported in four smaller studies. Sieczkowska et al. included 32 paediatric patients with CD or UC in a prospective study where patients were switched from the IFX originator to the biosimilar Remsima. The biosimilar was well tolerated and just as effective as the originator. 13 In a retrospective registration of adult patients with CD or UC, Jung et al. described both anti-TNF-α-naive patients introduced to biosimilar CT-P13 [n=74] and patients switching from the originator to its biosimilar, CT-P13 [n=36].
11 They found the efficacy and safety of the biosimilar to be comparable to that of the originator. A post-marketing study from South Korea reported week 30 data [after switching to CT-P13] in 46 patients and showed that 29/35 CD and 11/11 UC patients did not experience disease worsening. 10 Smits et al. recently published a prospective study including 83 IBD patients with both UC and CD switching from Remicade to CT-P13. 12 They demonstrated that switching did not have a significant impact on short-term clinical outcomes; however, the follow-up was only 16 weeks. In general, our findings confirm the results of the previous smaller studies. The present study included a large real-life IBD sample with 6 months of standardized prospective follow-up 
